Edoxaban tosylate

被引：7

作者：

机构：

来源：

American Journal of Cardiovascular Drugs | 2011年 / 11卷 / 2期

关键词：

Edoxaban;

D O I：

10.2165/11533660-000000000-00000

中图分类号：

学科分类号：

摘要：

Daiichi Sankyo is developing edoxaban tosylate (DU 176b; DU-176; DU-176b; DU176b) as an orally active direct factor Xa inhibitor for the prevention of stroke and the prevention and treatment of venous thromboembolism. Two dosing regimens of edoxaban tosylate are being compared with warfarin over 24 months in the ENGAGE AF TIMI 48 trial (NCT00781391) in over 21000 patients with atrial fibrillation in North and South America, Africa, Asia, Europe, Australia, and New Zealand. Edoxaban tosylate is also being compared with warfarin in the treatment and prevention of recurrent thromboembolic events in approximately 7500 patients with deep-vein thrombosis andor pulmonary embolism in the HOKUSAI VTE trial (NCT00986154) being conducted in 40 countries. This review discusses the development history and scientific profile of this new compound. © 2011 Adis Data Information BV. All rights reserved.

引用

页码：129 / 135

页数：6